Read More Pharma Industry News A one-time lupus reset? Why CTA313 is forcing competitors to rethink strategy Can CTA313 disrupt lupus markets with one-time remission? Explore how Imviva Biotech is reshaping autoimmune competition. bySoujanya RaviMay 2, 2026